3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
17
Thoracic
11
Dermatologic
9
Genitourinary
8
Lymphoid
6
Breast
5
Gastrointestinal
3
Plasma cell
2
Other hematologic neoplasm
2
Head & Neck
2
Gynecologic
2
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
CNS
1
Conditions
Sarcoma
22
Melanoma
6
Histiocytoma, Malignant Fibrous
6
Gastrointestinal Stromal Tumors
5
Osteosarcoma
4
Neoplasm Metastasis
4
Gliosarcoma
4
Neuroblastoma
3
Hemangiosarcoma
3
Chordoma
3
Bone Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Liposarcoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Interventions
Cyclophosphamide
17
pembrolizumab
12
Doxorubicin
10
fludarabine
7
Irinotecan
7
Blood Specimen Collection
7
Temozolomide
6
Gemcitabine
6
Etoposide
6
Radiotherapy
5
Ifosfamide
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
tecogalan
4
cemiplimab
4
Vincristine
4
Trabectedin
4
Paclitaxel
4
Nivolumab
4
Filgrastim
4
Drug Therapy
4
Dexamethasone
4
Bevacizumab
4
pazopanib
3
olaparib
3
nilotinib
3
dostarlimab
3
aflibercept
3
Therapeutics
3
Taxes
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Ipilimumab
×
Sarcoma
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts